{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:19:34Z","timestamp":1793647174424,"version":"4.5.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/j.curtheres.2017.01.005","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:01:54Z","timestamp":1486080114000},"page":"4-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review"],"prefix":"10.1016","volume":"84","author":[{"given":"Thangavel Mahalingam","family":"Vijayakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayasutha","family":"Jayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Meghana Cheekireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasari","family":"Himaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalamanchili","family":"Dharma Teja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damodharan","family":"Narayanasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2017.01.005_bib1","first-page":"365","article-title":"Bioequivalence comparison of Two Formulations of Fixed-Dose Combination Glimepiride\/metformin (2\/500 mg) Tablets in Healthy Volunteers","volume":"13","author":"Jung","year":"2014","journal-title":"IJPR"},{"key":"10.1016\/j.curtheres.2017.01.005_bib2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2147\/DDDT.S75980","article-title":"A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects","volume":"9","author":"Park","year":"2015","journal-title":"Drug Des. Dev. Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib3","first-page":"S110","article-title":"Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus","volume":"16","author":"Ved","year":"2012","journal-title":"IJEM"},{"key":"10.1016\/j.curtheres.2017.01.005_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diabet.2015.03.007","article-title":"Treatment maintenance duration of dual therapy with metformin and Sitagliptin in type 2 diabetes: The ODYSEE observational study","volume":"41","author":"Valensi","year":"2015","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.curtheres.2017.01.005_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.diabres.2013.08.001","article-title":"Acarbose plus metformin fixed-dose combination outperforms acarbosemonotherapy for type 2 diabetes","volume":"102","author":"Wang","year":"2013","journal-title":"Diabetes Res ClinPract"},{"key":"10.1016\/j.curtheres.2017.01.005_bib6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.clinthera.2011.07.016","article-title":"Adherence to Oral Antidiabetic Agents with Pioglitazone and metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy","volume":"33","author":"Barner","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clinthera.2015.11.010","article-title":"Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects","volume":"38","author":"Boulton","year":"2016","journal-title":"Clin. Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/dmt.12.31","article-title":"Evaluation of the bioequivalence of a fixed dose combination tablet of pioglitazone-metformin versus commercial tablets in healthy Japanese male volunteers","volume":"2","author":"Hiroi","year":"2012","journal-title":"Diabetes Manag"},{"key":"10.1016\/j.curtheres.2017.01.005_bib9","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.clinthera.2004.12.018","article-title":"Adherence to a Fixed-Dose Combination of Rosiglitazone Maleate\/Metformin Hydrochloride in Subjects with Type 2 Diabetes Mellitus: A Retrospective Database Analysis","volume":"26","author":"Vanderpoel","year":"2004","journal-title":"Clin.Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2005.10.012","article-title":"Rosiglitazone\/Metformin Fixed-Dose Combination Compared with Uptitrated Metformin Alone in Type 2 Diabetes mellitus: A 24-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study","volume":"27","author":"Bailey","year":"2005","journal-title":"Clin. Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib11","unstructured":"Avandamet\u00ae (rosiglitazone and metformin hydrochloride). Full prescribing information, GlaxoSmithKline, Research Triangle Park, NC.2008. Available at: https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Avandamet\/pdf\/AVANDAMET-PI-MG.PDF. Accessed March 28, 2016."},{"key":"10.1016\/j.curtheres.2017.01.005_bib12","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with Type 2 Diabetes","volume":"30","author":"Goldstein","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.curtheres.2017.01.005_bib13","unstructured":"JANUMET\u00ae (sitagliptin and metformin hydrochloride). Full prescribing information, Merck and Co, Whitehouse Station, NJ.2010. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/j\/janumet\/janumet_pi.pdf. Accessed March 28, 2016."},{"key":"10.1016\/j.curtheres.2017.01.005_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jdiacomp.2008.09.002","article-title":"Efficacy of glimepiride\/metformin combination versus glibenclamide\/ metformin in patients with uncontrolled type 2 diabetes mellitus","volume":"23","author":"Gonz\u00e1lez-Ortiz","year":"2009","journal-title":"J. Diabetes Complicat"},{"key":"10.1016\/j.curtheres.2017.01.005_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.clinthera.2011.10.003","volume":"33","author":"Shin","year":"2011","journal-title":"Clin. Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1726-4901(08)70044-3","article-title":"Effect of Glyburide-Metformin Combination Tablet in Patients with Type 2 Diabetes","volume":"70","author":"Chien","year":"2007","journal-title":"Chin Med Assoc"},{"key":"10.1016\/j.curtheres.2017.01.005_bib17","unstructured":"GLUCOVANCE\u00ae (glyburide and metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, Nj.2010. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021178s012lbl.pdf."},{"key":"10.1016\/j.curtheres.2017.01.005_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/251485","article-title":"Treatment Compliance with Fixed-Dose Combination of Vildagliptin\/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study","volume":"2015","author":"Rombopoulos","year":"2015","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.curtheres.2017.01.005_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00044011-200828090-00004","article-title":"Fixed Dose Combination Tablet of Repaglinide and Metformin is Bioequivalent to Concomitantly Administered Individual Tablets of Repaglinide and Metformin","volume":"28","author":"Hoelscher","year":"2008","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.curtheres.2017.01.005_bib21","unstructured":"PRANDIMET\u00ae (repaglinide and metformin hydrochloride). Full prescribing information, Novo Nordisk, Princeton, NJ.2010. Available at: http:\/\/www.novo-pi.com\/prandimet.pdf. Accessed March 28, 2016."},{"key":"10.1016\/j.curtheres.2017.01.005_bib22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40261-012-0012-6","article-title":"Pharmacokinetics of a Fixed-Dose Combination of Mitiglinide and Metformin versus Concurrent Administration of Individual Formulations in Healthy Subjects","volume":"32","author":"Jung","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.curtheres.2017.01.005_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/dc14-2365","article-title":"Initial Combination of Empagliflozin and Linagliptin in Subjects with Type 2 Diabetes","volume":"38","author":"Lewin","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.curtheres.2017.01.005_bib24","unstructured":"METAGLIP\u00ae (glipizide and metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, NJ.2009. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021460s007lbl.pdf. Accessed March 28, 2016."},{"key":"10.1016\/j.curtheres.2017.01.005_bib25","unstructured":"AVANDARYL\u00ae (rosiglitazone and glimepiride). Full prescribing information, GlaxoSmithKline, Research Triangle Park, NC.2009. Available at: https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Avandaryl\/pdf\/AVANDARYL-PI-MG.PDF. Accessed March 28, 2016."},{"key":"10.1016\/j.curtheres.2017.01.005_bib26","unstructured":"DUETACT\u00ae (pioglitazone and glimepiride). Full prescribing information, Takeda Pharmaceuticals America, Deerfield, IL.2010. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021925s010s011lbl.pdf. Accessed March 28, 2016."},{"key":"10.1016\/j.curtheres.2017.01.005_bib27","unstructured":"KOMBIGLYZE XR\u00ae (saxagliptin and extended-release metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, NJ.2010. Available at: http:\/\/www.azpicentral.com\/kombiglyze-xr\/pi_kombiglyze_xr.pdf. Accessed March 28, 2016."},{"key":"10.1016\/j.curtheres.2017.01.005_bib28","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1185\/03007990903297741","article-title":"Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence","volume":"25","author":"Balu","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.curtheres.2017.01.005_bib29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.clinthera.2010.07.012","article-title":"Comparison of the Bioavailability and Tolerability of Fixed-Dose Combination Glimepiride\/Metformin 2\/500-mg Tablets Versus Separate Tablets: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Korean Volunteers","volume":"32","author":"Gu","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib30","first-page":"129","article-title":"Effectiveness and safety of fixed dose combination of acarbose\/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study","volume":"19","author":"Saboo","year":"2016","journal-title":"IJEM"},{"key":"10.1016\/j.curtheres.2017.01.005_bib31","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.2337\/dc10-0159","article-title":"Initial Combination Therapy with Alogliptin and Pioglitazone in Drug-Na\u00efve Patients with Type 2 Diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.curtheres.2017.01.005_bib32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.clinthera.2005.09.003","article-title":"Long-term Effects of Glimepiride or Rosiglitazone in Combination with Metformin on Blood Pressure Control in Type 2 Diabetic Patients Affected by the Metabolic Syndrome: A 12-Month, Double-Blind, Randomized Clinical Trial","volume":"27","author":"Derosa","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib33","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.clinthera.2015.05.004","article-title":"Bioequivalence, Food Effect and Steady-State Assessment of Dapagliflozin\/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects","volume":"37","author":"Chang","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2017.01.005_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF03256914","article-title":"Bioequivalence of Sitagliptin\/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects","volume":"30","author":"Migoya","year":"2010","journal-title":"Clin Drug Investig"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X16300996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X16300996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T13:24:46Z","timestamp":1536067486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X16300996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":33,"alternative-id":["S0011393X16300996"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2017.01.005","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2017.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}